Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
Runhui Wu,1 Jing Sun,2 Weiqun Xu,3 Qun Hu,4 Wenqian Li,5 Jianwen Xiao,6 Feng’e Yang,7 Xiaojing Zeng,8 Yun Zeng,9 Jianfeng Zhou,4 Irina Matytsina,10 Sali Zhang,11 Michael Pluta,12 Renchi Yang13 1Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, N...
Main Authors: | Wu R, Sun J, Xu W, Hu Q, Li W, Xiao J, Yang F, Zeng X, Zeng Y, Zhou J, Matytsina I, Zhang S, Pluta M, Yang R |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-06-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/safety-and-efficacy-of-turoctocog-alfa-in-the-prevention-and-treatment-peer-reviewed-article-TCRM |
Similar Items
-
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study
by: Steven R. Lentz, et al.
Published: (2022-02-01) -
Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C
by: Napolitano M, et al.
Published: (2021-01-01) -
Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro
by: Masahiro Takeyama, et al.
Published: (2020-10-01) -
Cost analysis comparison of rurioctocog alfa pegol compared to turoctocog alfa pegol in the prophylaxis of Haemophilia A in Italy
by: Federica Demma, et al.
Published: (2022-06-01) -
Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective
by: Benson G, et al.
Published: (2021-01-01)